- Home
- NJR vs DNTH Comparison
NJR vs DNTH Comparison
Compare NJR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NJR | DNTH |
|---|---|---|
| Founded | 1922 | 2015 |
| Country | United States | United States |
| Employees | 1376 | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.6B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NJR | DNTH |
|---|---|---|
| Price | $56.19 | $87.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $53.75 | ★ $121.00 |
| AVG Volume (30 Days) | 388.8K | ★ 540.5K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 14.04 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $1,351,305,000.00 | $2,036,000.00 |
| Revenue This Year | $11.42 | N/A |
| Revenue Next Year | $2.12 | $29.48 |
| P/E Ratio | $46.43 | ★ N/A |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $43.46 | $16.77 |
| 52 Week High | $57.70 | $96.50 |
Technical Indicators
Market Signals| Indicator | NJR | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 55.23 | 54.40 |
| Support Level | $54.88 | $33.94 |
| Resistance Level | $57.23 | $88.45 |
| Average True Range (ATR) | 0.92 | 3.93 |
| MACD | -0.07 | -1.43 |
| Stochastic Oscillator | 69.31 | 38.75 |
Price Performance
Historical ComparisonAbout NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.